Ore Pharmaceutical Holdings Inc.
One Main Street
Suite 300
Cambridge,
MA 02142
United States - Map
Phone: 617-649-2001
Web Site: http://www.orepharma.com
| Ore Pharmaceutical Holdings Inc., through its wholly owned subsidiary, Ore Pharmaceuticals Inc., operates as a drug development company in the United States. Its drug candidates include GL1001, the lead drug candidate that completed a multiple ascending dose Phase I clinical trial, for the treatment of inflammatory bowel disease; tiapamil for treatment of diseases of central nervous system, primarily focused on cognition and memory; and romazarit, a clinical-stage drug candidate for the treatment of metabolic indications, such as obesity. The company was founded in 1994 and is headquartered in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Mark J. Gabrielson ,
Chief Exec. Officer, Pres, Treasurer |
$
77.00K | N/A | Mr. Benjamin L. Palleiko , 44
Chief Financial Officer and Sr. VP |
N/A
| N/A | Dr. Thomas Barnes Ph.D.,
Sr. VP of Discovery |
N/A
| N/A | Dr. Stephen R. Donahue M.D., 46
Sr. VP of Clinical Devel. |
N/A
| N/A | Mr. Chris T. Dunne ,
Principal Accounting Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.02% Nasdaq 
0.33%
Profile
